Foresite Capital Management VI LLC Increases Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Foresite Capital Management VI LLC raised its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 3.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,364,019 shares of the company’s stock after purchasing an additional 50,000 shares during the quarter. Centessa Pharmaceuticals comprises 10.3% of Foresite Capital Management VI LLC’s portfolio, making the stock its 4th largest holding. Foresite Capital Management VI LLC owned about 1.01% of Centessa Pharmaceuticals worth $34,114,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Avoro Capital Advisors LLC boosted its stake in Centessa Pharmaceuticals by 116.2% during the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after buying an additional 5,808,080 shares in the last quarter. Maverick Capital Ltd. purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth about $41,110,000. Adage Capital Partners GP L.L.C. raised its holdings in Centessa Pharmaceuticals by 20.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock worth $110,415,000 after buying an additional 1,449,000 shares during the period. Balyasny Asset Management L.P. purchased a new stake in Centessa Pharmaceuticals during the second quarter valued at about $16,052,000. Finally, Sofinnova Investments Inc. acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth about $27,618,000. Institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on CNTA shares. Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Leerink Partners lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and increased their price objective for the company from $36.00 to $40.00 in a report on Wednesday, April 1st. Truist Financial cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price objective for the company. in a research note on Monday, April 13th. Needham & Company LLC downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Finally, Guggenheim downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $41.33.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 41,076 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the transaction, the insider owned 62,085 shares in the company, valued at approximately $1,870,000.20. The trade was a 39.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.09% of the stock is owned by corporate insiders.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $39.76 on Tuesday. The firm has a market capitalization of $6.15 billion, a PE ratio of -22.21 and a beta of 1.11. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $12.05 and a 1-year high of $40.26. The business’s 50 day moving average is $39.64 and its 200-day moving average is $30.96.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.